Lower frequencies of circulating suppressive regulatory T cells and higher frequencies of CD4⁺ naive T cells at baseline are associated with severe immune-related adverse events in immune checkpoint inhibitor-treated melanoma.

ABSTRACT:

Background

Immune-related adverse events (irAEs) are major barriers of clinical management and further development of immune checkpoint inhibitors (ICIs) for cancer therapy. Therefore, biomarkers associated with the onset of severe irAEs are needed. In this study, we aimed to identify immune features detectable in peripheral blood and associated with the development of severe irAEs that required clinical intervention.

Methods

We used a 43-marker mass cytometry panel to characterize peripheral blood mononuclear cells from 28 unique patients with melanoma across 29 lines of ICI therapy before treatment (baseline), before the onset of irAEs (pre-irAE) and at the peak of irAEs (irAE-max). In the 29 lines of ICI therapy, 18 resulted in severe irAEs and 11 did not.

Results

SUBMITTER: Kovacsovics-Bankowski M 

PROVIDER: S-EPMC10806651 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature